| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCEA2 |
| Uniprot No | Q15560 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-299aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMMGKEEEIARIARRLDKMVTKKSAEGA MDLLRELKAMPITLHLLQSTRVGMSVNALRKQSSDEEVIALAKSLIKSWK KLLDASDAKARERGRGMPLPTSSRDASEAPDPSRKRPELPRAPSTPRITT FPPVPVTCDAVRNKCREMLTAALQTDHDHVAIGADCERLSAQIEECIFRD VGNTDMKYKNRVRSRISNLKDAKNPDLRRNVLCGAITPQQIAVMTSEEMA SDELKEIRKAMTKEAIREHQMARTGGTQTDLFTCGKCRKKNCTYTQVQTR SSDEPMTTFVVCNECGNRWKFC |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCEA2重组蛋白的3篇参考文献的简要概括：
1. **"Expression and purification of recombinant human TCEA2 in Escherichia coli"**
- 作者：Li Y, et al.
- 摘要：该研究报道了通过大肠杆菌表达系统成功表达并纯化人源TCEA2重组蛋白的优化方法，分析了蛋白的可溶性和活性，为后续功能研究提供了材料基础。
2. **"Functional characterization of TCEA2 in transcriptional regulation and DNA repair"**
- 作者：Smith J, et al.
- 摘要：研究利用重组TCEA2蛋白进行体外生化实验，揭示其作为转录延伸因子的作用机制，并发现其参与DNA损伤修复的新功能，提示其在细胞应激反应中的重要性。
3. **"Structural analysis of TCEA2 reveals conserved domains critical for RNA polymerase II interaction"**
- 作者：Wang H, et al.
- 摘要：通过X射线晶体学解析重组TCEA2蛋白的三维结构，鉴定了与RNA聚合酶II结合的关键结构域，为理解其调控基因转录的分子机制提供了结构依据。
注：以上文献信息为示例性概括，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。若需具体文献，建议结合最新研究进展补充检索。
**Background of TCEA2 Recombinant Protein**
TCEA2 (Transcription Elongation Factor A2), also known as TFIIS, is a critical regulatory protein involved in transcription elongation by RNA polymerase II (Pol II). It belongs to the TFIIS family, which plays a role in resolving transcriptional pausing or backtracking, ensuring efficient synthesis of mRNA. Structurally, TCEA2 contains conserved domains that interact with Pol II, facilitating the read-through of problematic DNA regions and maintaining transcriptional fidelity.
The recombinant TCEA2 protein is engineered through molecular cloning and expression in heterologous systems (e.g., *E. coli* or mammalian cells), allowing large-scale production of purified, functional protein. Recombinant versions retain the ability to bind Pol II and stimulate its elongation activity, making them valuable tools for *in vitro* studies of transcription mechanisms.
Research on TCEA2 has implications in understanding diseases linked to transcriptional dysregulation, including cancers and neurodegenerative disorders. For instance, aberrant transcription elongation is associated with oncogene activation or tumor suppressor silencing. Additionally, TCEA2 interactions with viral polymerases highlight its role in viral replication studies.
The availability of recombinant TCEA2 enables structural studies (e.g., crystallography), biochemical assays, and drug screening aimed at modulating transcription elongation. Its application extends to developing therapies targeting transcription-related pathologies. Overall, TCEA2 recombinant protein serves as a pivotal resource for dissecting transcriptional regulation and its disease connections.
×
